Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

Prior treatment

• Prior exposure to anti-p19 biological therapy
• Exclude any previous use of p19 IL23s agents
• Concomitant Clostridioides difficile infection

Other illness

• Exposure to more than 1 class of advanced therapies at a dose approved for the treatment of Crohn's disease (janus kinase \[JAK\] inhibitors, infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab, or approved biosimilars for these agents
• HIV infection

Other

• Contra-indication to mirikizumab
• Definitive ostomy
• Colectomy with IPAA
• Isolated or uncontrolled perianal lesions
• Severe obstructive symptoms
• Intra-abdominal abscess
• Contra-indication to MRI
• No health insurance
• Pregnant or lactating women
• Patients already included in biomedical research other than an observational study (e.g., registry, cohort)
• Patient under guardianship, curatorship or safeguard of justice

• Patients with CD
• ≥ 18 to ≤ 75 years-old
• Symptomatic CD according to PRO-2 (stool \> 3 or abdominal pain score \> 1)
• Transmural inflammation on baseline MRI (C-score \> 0.5 in at least one segment)